OPDIVO

targets

all catalysts(0)

nothing on the calendar yet

News(10)

• BMO most bullish on Merck's, bearish on BMS’ plans to contend with patent cliffs
  BMO Capital Markets is more impressed by Merck’s plans to replace lost Keytruda revenue than on Bristol Myers Squibb’s efforts to fill the expected void that will come from loss of exclusivity for…
  biospace · 2d ago
• Unlocking cell surface protein research with site-specific labeling
  Applications in flow cytometry, cell sorting, target validation, and therapeutic discovery
  biospace · 21d ago
• 5 drugmakers chasing Merck and Moderna in the cancer vaccine race
  Following their blowout win in melanoma last month, Merck and Moderna are leading the way among a new crop of personalized cancer vaccines. Here are five companies with similar therapies hoping to…
  biospace · 21d ago
• A new immuno-oncology play raises $225M for a next-generation drug
  Solstice Oncology is advancing a medicine from China’s Harbour BioMed that it believes is able to address the weaknesses of drugs aimed at CTLA-4, a popular but tricky cancer immunotherapy target.
  biopharma_dive · 25d ago
• Akeso, Summit cancer drug confirms lung cancer survival benefit
  A new data cut of a trial pitting ivonescimab, a bispecific antibody, against Merck’s Keytruda showed the new drug helped people live longer.
  biopharma_dive · 1mo ago
• Replimune’s melanoma drug would have been rejected again if not for senior CBER official
  The FDA’s primary review team found that Replimune hadn’t sufficiently addressed deficiencies that had been pointed out in the two prior rejection letters for the melanoma therapy Tudriqev.
  biospace · 1mo ago
• Stripped of AstraZeneca safety net, BMS could face ‘carnage’ if high-risk clinical trial fails
  BMS is barreling toward a clinical trial readout that an H.C. Wainwright analyst believes could contribute to the return of mergers between mega-cap drugmakers.
  biospace · 1mo ago
• Capricor, Replimune reviews signal FDA’s return to reliability but every application will stand alone
  Following a tumultuous stretch under ex-Commissioner Marty Makary, current FDA leadership is working to restore reliability, integrity and transparency to the agency—but experts say that doesn’t ne…
  biospace · 1mo ago
• AstraZeneca scraps Phase 3 trial of new bispecific in lung cancer
  An interim data check revealed that survival goals were likely to be missed by volrustomig, one in a list of new drugs the U.K. company is leaning on to meet an $80 billion sales goal.
  biopharma_dive · 1mo ago
• BMS picks Texas for new $2.3B manufacturing campus
  Bristol Myers Squibb’s $2.3 billion Houston manufacturing campus is part of the company’s larger $40 billion investment designed to bolster American innovation and manufacturing.
  biospace · 1mo ago